In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home

Executive Summary

Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players who have enjoyed success on their own turf will become a global threat.

You may also be interested in...



Corporate Responsibility With Teeth: GSK’s Developing Countries Unit

Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.

Deals Of The Week: Russia Says “Nyet” To Abbott’s Buyout Of Domestic Vaccine Company

As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.

Off The WHO Hook, Sanofi CEO Viehbacher Plans To Take Shantha's Vaccines To The World

HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel